Table II.
Haemostatic parameters on days 1, 3 and 5 in Mirasol-treated and control platelets
| Parameter/Day | Median (IQR) | p-value | |
|---|---|---|---|
| Mirasol | Control | ||
| LTA ADP(%), 1 | 30.5 (24–47) | 27.5 (10–57) | 0.623 |
| LTA ADP(%), 3 | 14 (9–20) | 3 (2–3) | <0.001 |
| LTA ADP(%), 5 | 11 (11–14) | 2 (1–3) | <0.001 |
| p-value | 0.002 | 0.002 | |
| LTA EPI(%), 1 | 23 (21–40) | 16 (9–26) | 0.150 |
| LTA EPI(%), 3 | 13 (12–28) | 9 (6–11) | 0.019 |
| LTA EPI(%), 5 | 14 (12–16) | 7 (7–10) | 0.002 |
| p-value | 0.008 | 0.016 | |
| P-selectin(%), 1 | 3.5 (2.4–20.1) | 0.6 (0.3–3.5) | 0.055 |
| P-selectin(%), 3 | 17.9 (12.8–34.7) | 6.6 (2.2–6.8) | 0.003 |
| P-selectin(%), 5 | 22.8 (19.7–35) | 6.4 (2.7–12.1) | 0.002 |
| P-value | 0.026 | 0.016 | |
| ETP AUC(%), 1 | 86.5 (79–91) | 86 (80–96) | 0.596 |
| ETP AUC(%), 3 | 78 (66–80) | 87 (82–91) | 0.038 |
| ETP AUC(%), 5 | 65 (46–81) | 86 (76–93) | 0.019 |
| p-value | 0.037 | 0.863 | |
| ETP Cmax(%), 1 | 79.5 (73–85) | 93.5 (87–104) | 0.019 |
| ETP Cmax(%), 3 | 73 (68–77) | 98 (83–106) | <0.001 |
| ETP Cmax(%), 5 | 58 (44–66) | 89 (85–99) | <0.001 |
| p-value | <0.001 | 0.741 | |
| TAT(μg/L), 1 | 3.06 (2.80–3.31) | 2.89 (2.80–3.20) | 0.623 |
| TAT(μg/L), 3 | 3.65 (3.44–4.53) | 3.22 (2.63–3.64) | 0.059 |
| TAT(μg/L), 5 | 3.8 (3.6–4.4) | 3.2 (2.9–4.2) | 0.102 |
| p-value | 0.033 | 0.529 | |
| MPA(nM), 1 | 28.67 (23.83–33.23) | 34.71 (28.49–37.4) | 0.1152 |
| MPA(nM), 3 | 70.76 (41.41–83.3) | 43.51 (35.52–58.80) | 0.208 |
| MPA(nM), 5 | 85.42 (76.82–87.16) | 61.97 (53.59–78.46) | 0.015 |
| p-value | <0.001 | 0.004 | |
| CT EXTEM(sec), 1 | 53 (48–65) | 59 (51–66) | 0.535 |
| CT EXTEM(sec), 3 | 50 (47–65) | 55 (49–60) | 0.757 |
| CT EXTEM(sec), 5 | 55 (43–63) | 54 (45–61) | 0.930 |
| p-value | 0.759 | 0.698 | |
| A10 EXTEM(mm), 1 | 59 (59–62) | 66 (64–66) | 0.004 |
| A10 EXTEM(mm), 3 | 42 (38–46) | 59 (56–61) | <0.001 |
| A10 EXTEM(mm), 5 | 27 (23–38) | 53 (52–60) | <0.001 |
| p-value | <0.001 | 0.003 | |
| A10 FIBTEM(mm), 1 | 22 (20–23) | 23 (22–26) | 0.399 |
| A10 FIBTEM(mm), 3 | 22 (21–24) | 22 (20–24) | 0.929 |
| A10 FIBTEM(mm), 5 | 21 (18–21) | 20 (19–21) | 0.858 |
| p-value | 0.395 | 0.150 | |
| A20 EXTEM(mm), 1 | 63 (63–66) | 68 (68–69) | 0.010 |
| A20 EXTEM(mm), 3 | 39 (33–41) | 61 (56–63) | <0.001 |
| A20 EXTEM(mm), 5 | 27 (24–34) | 51 (48–58) | <0.001 |
| p-value | <0.001 | <0.001 | |
| A30 EXTEM(mm), 1 | 62 (62–65) | 67 (66–67) | 0.010 |
| A30 EXTEM(mm), 3 | 36 (32–37) | 58 (52–60) | <0.001 |
| A30 EXTEM(mm), 5 | 27 (25–31) | 47 (43–54) | <0.001 |
| p-value | <0.001 | <0.001 | |
| CFT EXTEM(sec), 1 | 53 (49–57) | 47 (45–55) | 0.199 |
| CFT EXTEM(sec), 3 | 55 (50–58) | 50 (39–62) | 0.691 |
| CFT EXTEM(sec), 5 | 57 (53–77) | 46 (42–58) | 0.144 |
| p-value | 0.405 | 0.973 | |
| MCF EXTEM(mm), 1 | 63 (63–66) | 68 (68–69) | 0.009 |
| MCF EXTEM(mm), 3 | 44 (41–46) | 61 (57–63) | <0.001 |
| MCF EXTEM(mm), 5 | 34 (30–43) | 53 (52–60) | <0.001 |
| p-value | <0.001 | <0.001 | |
| MCF FIBTEM(mm), 1 | 23 (21–25) | 25 (22–28) | 0.535 |
| MCF FIBTEM (mm), 3 | 24 (22–25) | 24 (22–26) | 0.965 |
| MCF FIBTEM (mm), 5 | 23 (21–23) | 20 (20–22) | 0.397 |
| p-value | 0.660 | 0.201 | |
| MCE EXTEM, 1 | 169 (167–191) | 212 (208–218) | 0.009 |
| MCE EXTEM, 3 | 79 (70–86) | 153 (133–170) | <0.001 |
| MCE EXTEM, 5 | 52 (43–76) | 115 (110–152) | <0.001 |
| p-value | <0.001 | <0.001 | |
p-values in bold show statistical significance (p<0.05).
IQR: interquartile range; LTA: light transmission aggregometry; ETP: endogenous thrombin potential; AUC: area under the curve; Cmax: peak thrombin generation; TAT: thrombin-antithrombin complex; MPA: microparticle procoagulant activity; CT: clotting time; A10: amplitude 10 minutes (min) after CT; A20: amplitude 20 min after CT; A30: amplitude 30 min after CT; CFT: clot formation time; MCF: maximum clot firmness; MCE: maximum clot elasticity.